Brazil’s health regulator Anvisa reported that Sputnik V COVID-19 vaccine 91.6% effective is different from the authorization requested by União Química, which represents the Russian laboratory Gamaleya in Brazil, says O Globo.

The Sputnik V vaccine has recorded a 91.6% efficacy rate against COVID-19, according to peer-reviewed results from its phase 3 clinical trial, as reported The Lancet international medical journal this Tuesday morning.

However, according to the Brazilian regulator, The Lancet released results of the liquid vaccine stored at -18ºC (-0.4ºF), while Brazilian pharmaceutical firm União Química proposes other conditions for temperature and storage. According to O Globo, Brazil’s regulator wants more data to find out if the results are the same.

One decision that may facilitate Sputnik V’s approval in Brazil is that Anvisa suspended the required phase 3 trials in Brazil to authorize the emergency use of a vaccine, according to CNN.